884results about "Amine active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention belongs to the technical field of medicines, and particularly relates to a composition for improving obesity and promoting cardiovascular health as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 5 to 20 parts of glycine betaine, 1 to 5.5 parts of choline chloride, 0.5 to 4 parts of L-theanine, 1 to 15 parts of alpha-ketoglutarate calcium, 0.5 to 3 parts of black ginger extract, 0.05 to 0.25 part of black pepper extract, 0.5 to 3 parts of ginkgo leaf extract and 1 to 6 parts of black garlic juice powder. According to the invention, the eight components are selected and are scientifically combined in an optimal quantity ratio range, and the prepared composition can better reduce the inflammation level of a body, regulate abnormal blood fat, improve the lipid metabolism disorder state and effectively reduce impulsive diet behaviors, so that comprehensive improvement of obesity and cardiovascular related risks is realized, and the health-care effect of a human body is improved. The body is effectively assisted to maintain metabolic health.

The invention belongs to the technical field of drug delivery systems, and discloses a two-dimensional vermiculite-based drug delivery system and a preparation method and application thereof. The preparation method comprises the following steps: carrying out ion exchange on expanded vermiculite, NaCl and LiCl, stripping by using a mechanical stripping sheet, centrifuging to obtain a two-dimensional vermiculite nanosheet dispersion liquid, dispersing a drug in the two-dimensional vermiculite nanosheet dispersion liquid, and forming a film to obtain the two-dimensional vermiculite-based drug delivery unit. The drug is synergistically loaded between layers and on the surface of the vermiculite; rich hydroxyl groups and interlayer cations on the end surface of the vermiculite interact with the drug, so that the drug release time is relatively long; the vermiculite-based drug delivery system can realize gradient order release of drugs according to a sequence from the surface to the interlayer through pH response of an affected part. Meanwhile, the vermiculite-based drug delivery system provides an antibacterial effect through enzyme-like catalytic activity, and avoids the problems of abuse of antibiotics and drug resistance.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

The present invention relates to intracellular copper zinc superoxide dismutase inhibitors for protecting a subject from damage caused by radiation outbreak. The invention also relates to kits comprising SOD1 inhibitors and radiosensitizers for cancer cells, to the in vitro use of SOD1 inhibitors for protecting non-cancer cells from ionizing radiation, and to methods, compositions and uses related thereto.

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.

Methods of treating a subject for a dissociative disorder and methods of screening agents for the ability to modulate dissociative and associative states in a subject are provided. In particular, agents that alter rhythmic neural activity in the posteromedial cortex can be used to modulate dissociative and associative states in a subject.

Described herein are pinoxifene compositions comprising novel compounds and methods of use thereof. Methods of synthesizing the compositions are described herein. The odoxifene compositions described herein may exhibit aromatase inhibitory activity or estrogen receptor activity. The odoxifene compositions described herein can be used to treat a condition, such as cancer, in a subject.

The invention discloses a triarylmethane type I photosensitive dye as well as a synthesis method and application thereof. The structure of the dye is shown as a general formula I; intramolecular charge separation is optimized by regulating substituent groups, and the generation efficiency of superoxide anions and hydroxyl radicals is remarkably improved. According to the synthesis method, 4-diphenylaminobenzaldehyde or 4-vinyl benzaldehyde is used as a raw material, efficient preparation is achieved through the steps of condensation, oxidation and the like, the raw material is easy to obtain, and operation is easy and convenient. The dye has strong absorption at the wavelength of 600-630 nm, is suitable for red light triggered photodynamic therapy (PDT), especially keeps high reactive oxygen yield under the hypoxic condition, and breaks through the oxygen dependence limitation of traditional PDT. Experiments show that the dye can induce ferroptosis of tumor cells, has the functions of fluorescence imaging and treatment, and has wide application prospects in the fields of antitumor drugs, in-vivo fluorescence labeling, photoresponsive functional preparations and the like.

To provide antisense oligonucleotide sequences and methods of using the same for treating neurological diseases.SOLUTION: Provided is an oligonucleotide comprising linked nucleosides having a sequence of at least 19 contiguous nucleobases, wherein the sequence of nucleobases comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary to an equal length portion of nucleobases contained at a specified position of a specified sequence.SELECTED DRAWING: Figure 1A

The invention discloses an ultrasonic response quaternary ammonium salt polymer antibacterial agent and a preparation method thereof. The ultrasonic response quaternary ammonium salt polymer is prepared by the following steps: carrying out substitution reaction on azodiisobutylimidazoline and acryloyl chloride, then carrying out addition polymerization reaction with 4-aminomethylpiperidine, and then carrying out quaternization reaction with bromohexane. The obtained ultrasonic response quaternary ammonium salt polymer can be decomposed under the ultrasonic action to generate alkyl radicals, and has the sterilization effect. In addition, quaternary ammonium salt modification can improve the water solubility and the positive charge density of the polymer, and further improves the antibacterial performance.

The present invention relates to an inhibitor of intracellular copper-zinc-superoxide dismutase for use in protecting a subject from injury by a radiation burst. The present invention also relates to a kit comprising an SOD1 inhibitor and a radiosensitizer of cancer cells, to an in vitro use of an SOD1 inhibitor for protecting non-cancer cells from ionizing radiation, and to methods, compositions, and uses related thereto.

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

The invention provides a novel antibacterial and anti-inflammatory functional additive, a preparation method and application, and belongs to the technical field of biological materials, the additive is organic-inorganic hybrid nanoparticles, and is formed by self-assembly of metal ions, natural polyphenol compounds and quaternary ammonium salt compounds. According to the antibacterial / anti-inflammatory functional additive disclosed by the embodiment of the invention, the antibacterial / anti-inflammatory functional additive has the effects of high biocompatibility, rapid active sterilization, long-acting passive bacteriostasis and inflammation immunity regulation and control.

Provided are a novel antibacterial agent having a high safety and long-lasting effect, an antibacterial composition and an antiviral composition.　The antibacterial agent of the present invention is a formulation comprising the following components (A) and (B). (A) An amine or an ammonium compound having a hydrogen-bonding functional group (excluding an amino acid). (B) A carboxylic acid or a salt thereof.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

The invention provides novel pharmaceutical compositions of polymyxin B / trimethoprim and rifampin, as well as methods of their preparation and topical ophthalmic uses (e.g., treatment of ophthalmic infections).

To provide the use of a compound for manufacturing a reagent for efficient in vivo delivery of nucleic acid molecules, including small RNA, to a target organ and a target cell.SOLUTION: The invention provides the use of a compound derived naturally (including a traditional Chinese medicine extract) or synthetically for the manufacture of a nucleic acid delivery reagent, where the compound is represented, e.g., by the formula in the figure.SELECTED DRAWING: None

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

To provide development of health food supplements and antioxidants for controlling hyperuricemia and oxidative stress.SOLUTION: Embodiments of the disclosure include methods and compositions that comprise one or more herb extracts and optionally folic acid and / or one or more of its derivatives. In specific embodiments, the disclosure concerns treatment or prevention of hyperuricemic conditions with combinatorial compositions, such as those including one or more Chinese herbal medicine extracts and optionally folic acid and / or one or more of its derivatives.SELECTED DRAWING: None

A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, Vitamin B12 and choline. The composition is administered in a daily dose that provides 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 per day and 0.01 to 10.0 times the recommended daily requirement (RDA) of choline. Optionally Vitamin B6 and / or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuro inflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

The present invention relates to methods of increasing dopamine levels in a subject. The present invention also relates to the treatment of conditions or disorders involving reduced dopamine levels, and to medicaments for use in such treatment.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a traditional Chinese medicine compound antibacterial gel for promoting blood circulation to remove meridian obstruction and a preparation method thereof. The traditional Chinese medicine compound antibacterial gel for promoting blood circulation to remove meridian obstruction is prepared from the following components in percentage by mass: 0.01 to 0.03 percent of benzalkonium chloride, 0.02 to 0.05 percent of aromatic phenol acetate, 1 to 2.5 percent of propylene glycol, 0.01 to 0.05 percent of menthol, 0.3 to 0.6 percent of traditional Chinese medicine extracting solution, 0.01 to 0.05 percent of ginger root oil, 0.5 to 1 percent of pandan butyl ether, 0.01 to 0.05 percent of borneol, 0.3 to 5 percent of modified hydroxyethyl cellulose and the balance of water. The gel can relieve tissue edema and improve microcirculation and tissue oxygen supply; meanwhile, by combining with antibacterial components, the anti-infection effect can be synchronously achieved, the effects and advantages of promoting blood circulation and dredging collaterals of the traditional Chinese medicine compound are complementary, the better treatment effect is achieved, and the wound healing quality and speed are improved.